Background
==========

Primary neuroendocrine carcinoma of the breast (NECB) was originally described in breast cancers with carcinoid-like growth patterns \[[@B1],[@B2]\]. Subsequent reports have been used to define the common features of NECB by combining histologic findings with ultrastructural, molecular, and immunohistochemical data \[[@B3],[@B4]\]. Because it can mimic some of the most common histologic subtypes of breast cancer, primary NECB is difficult to diagnose and therefore remains under-recognized. Herein we report the case of a patient initially diagnosed with invasive ductal carcinoma (IDC) that was postoperatively found to have a primary NECB. Additionally we provide a comprehensive review of the literature encompassing detailed information regarding epidemiology, histogenesis, clinical and histologic diagnosis criteria, classification, surgical and adjuvant treatment, as well as prognosis. We also provide recommendations for common clinical and histologic pitfalls.

Case presentation
=================

A 51-year-old Hispanic woman with no previous medical history presented with a self-detected lump in her right breast. Physical examination revealed a 2.0 cm firm mass in the outer quadrants of the right breast, which was adhered to the chest wall. The left breast and both axillae were normal. Mammography revealed a distinctive mass with microscopic calcifications and spiculation signs in the upper-outer quadrant of the right breast (BI-RADS 3). A core needle biopsy of the mass reported high-grade IDC. Staging workup, which included a chest CT and a liver ultrasound, was negative for metastatic disease.

The patient was staged with a locally advanced IIIB (T4aN0M0) breast cancer and underwent neoadjuvant therapy consisting of four cycles of doxorubicin and cyclophosphamide followed by 33 sessions of radiation therapy (total dose, 66 Gy to the site of the tumor and 50 Gy to the rest of the breast and axilla). During the course of treatment the tumor did not show any significant change in size; accordingly the patient underwent right modified radical mastectomy.

On gross examination, a 3.2×1.2 cm firm, grey mass with infiltrating margins was noted. Histopathologically the tumor was characterized by small, uniform cancer cells growing in nests and alveolar-like structures surrounded by delicate fibrovascular stroma and collagen that invaded ducts and ductules (Figure [1](#F1){ref-type="fig"}). Cancer cells were polygonal, round, and oval shape and had finely granular nuclear chromatin with uniform and vesicular nuclei and relatively eosinophilic cytoplasm. Due to these features immunohistochemistry (IHC) with neuroendocrine markers was performed. Cancer cells stained positive for both synaptophysin and chromogranin A (individual reactivity rate 100%) (Figure [1](#F1){ref-type="fig"}). A high-grade IDC component was also observed within the same tumor. Cancer cells were positive for estrogen receptors (ER) (reactivity rate 90%) and negative for progesterone receptors (PR) and HER-2 (HercepTest™ score 0). The Ki-67 proliferation index was \>20%. Axillary lymph nodes did not harbor metastases. Based on these histological findings the tumor was classified as an alveolar-type invasive NECB with IDC.

![**Histopathological findings of the primary alveolar-type neuroendocrine carcinoma of the breast.**The tumor showed solid nests of cancer cells growing in alveolar-like patterns, which were separated by fibrovascular stroma and collagen and infiltrated the ducts and ductules (**A**). The neuroendocrine tumor component showed diffuse positive immunoreactivity to chromogranin A (**B**) and synaptophysin (**C**) (original magnification: A: 10× and B, C: 40×).](1477-7819-11-128-1){#F1}

Postoperatively, the patient was treated with three cycles each of cisplatin/etoposide followed by paclitaxel/carboplatinum. She was also started on hormone therapy (tamoxifen then switched to letrozole). Thirteen months after surgery the patient was alive, but she unfortunately developed pulmonary, bone, and hepatic metastases.

Discussion
==========

In the last 50 years histological and immunohistochemical studies have extended our knowledge about neuroendocrine tumors. Different diagnostic technologies allow us to distinguish pathological changes in endocrine cells. It is now possible to identify neuroendocrine features morphologically and biochemically within different histological types of invasive breast cancer. NECB was originally described in 1963 by Feyrter *et al.* when several cases of invasive breast cancer appeared to have a carcinoid growth pattern \[[@B1]\]. In 1977 Cubilla and Woodruff reported a case series of patients with breast tumors with the same features \[[@B2]\]. Later on in 1982 a modified silver stain (grimelius) and electron microscopy were both routinely used to identify neurosecretory granules and if present within a tumor the patient was diagnosed with 'argyrophilic breast carcinoma', a term coined by Azzopardi *et al.*\[[@B5]\]. Towards the end of the 1980s chromogranin and synaptophysin were found to be neuroendocrine differentiation markers and tumors that were once denominated 'argylophilic breast carcinoma' also tested positive for these markers \[[@B6]\]. It was only until 2002 when Sapino *et al.*\[[@B7]\] first suggested a specific definition for NECB, which was subsequently adopted by the World Health Organization (WHO) in 2003 as a means of endorsing it as a unique type of breast cancer \[[@B8]\]. In the WHO classification neuroendocrine tumors have been defined as those in which one or more neuroendocrine markers, such as neuro specific enolase, chromogranin A, and/or synaptophysin, are expressed in at least 50% of cancer cells \[[@B8]\]. In addition to this, diagnosing primary NECB also requires fulfilling two other criteria: (1) other primary sites must be ruled out and (2) the tumor must show histological evidence of a breast *in situ* component \[[@B9]\].

The prevalence of primary NECB was once reported to be as high as 12% to 19.5%, but this was based on early diagnostic criteria, various sources of tissue, and IHC neuroendocrine markers \[[@B10]-[@B13]\]. According to WHO diagnostic criteria the incidence is reported to actually range from 0.3% to 0.5% \[[@B14],[@B15]\]. The peer-reviewed literature reveals that \>80 patients have been reported (Table [1](#T1){ref-type="table"}). A significant proportion (59.8%) of these cases was published after the WHO definition was established in 2003 allowing for consistency with respect to diagnostic criteria. The majority of cases have been described in women and so far only two cases in men have been reported \[[@B16],[@B17]\]. The reported age of incidence ranges from 20 to 83 years with a higher incidence (60.2%) occurring in patients aged ≥50 years.

###### 

**Summary of primary neuroendocrine carcinoma of the breast cases published in the indexed literature (*n*=83)**^a^

                                                                             **Neuroendocrine IHC**   **Hormonal receptors**        **Treatment**                                                                   
  ----------------------------- ------- ------ --------- --------- -------- ------------------------ ------------------------ ---- --------------- ---- ---- ---- ---- ----------- --------------- ------- -------- -------
     Wade (1983) \[[@B18]\]      52/F     R      10.0     T4N1M0      \-               \-                                                           \+   NS   NS   NS      NS         Mast/ALND      Ch       9       DOD
     Jundt (1984) \[[@B16]\]     52/M     R       NS      TxN1M0      NS               \-                       \+                                  \+   NS   NS   NS      NS            NS         Ch/RT     14      DOD
    Papotti (1992) \[[@B19]\]    64/F     R       2.0     T1N0M0      \+               \-                       \-             \-        \-              \-   NS   NS      NS         Mast/ALND      NS       44      NED
              41/F                 L     3.5    T2NxM0      \+        \-               \+                       \-             \-        \+         \-   NS   NS   NS   Mast/ALND        RT          15      DOD    
              41/F                 L     3.0    T2NxM0      \+        \+               \+                       \+             \+        \+         \-   NS   NS   NS   Mast/ALND        Ch          14     LR/DOD  
              69/F                 L     5.0    T3NxM0      \+        \+               \+                       \-             \+                   \+   NS   NS   NS   Mast/ALND        HT           9      DOD    
    Papotti (1993) \[[@B17]\]    83/M     R       1.5     T1N0M0      \+               \+                       \+             \+                        \-   NS   NS      NS           Mast         NS       84      DOD
   Francois (1995) \[[@B20]\]    68/F     R       4.5     T2N0M0      NS                                                       \+                        \-   \-   NS      \-         Mast/ALND      RT       21     D-NOS
     Chua (1997) \[[@B21]\]      45/F     L       NS      T2N0Mx      NS               NS                       NS             NS        NS         NS   NS   NS   NS      NS            BCS         NS       NS      NS
   Fukunaga (1998) \[[@B22]\]    56/F     R      10.0     T3NxM0      \+                                                       \+        \+              \-   \-   NS      \-         Mast/ALND      \-       48      NED
     Samli (2000) \[[@B23]\]     60/F     L       8.0     T4N1M0      NS                                                       \+        \+              NS   NS   NS      Ch         Mast/ALND     Ch/RT     6       LR
     Shin (2000) \[[@B24]\]      43/F     R       1.3     T1NxM0      NS                                        \+                                       NS   NS   \-      \-            BCS         RT       30      NED
              44/F                 L     2.0    T1NxM0      NS                         \+                                                           NS   NS   \-   \-   BCS/ALND        Ch/RT        27      NED    
              46/F                 R     3.4    T2NxM0      NS                         \+                                                           NS   NS   \-   \-   Mast/ALND        Ch          11      AWM    
              50/F                 R     2.2    T2NxM0      \+                         \+                                                           NS   NS   \-   \-   BCS/ALND        Ch/HT        35      NED    
              51/F                 R     1.5    T1NxM0      NS                         \+                                                           NS   NS   \-   \-   BCS/ALND         RT          25      NED    
              57/F                 L     2.5    T2NxM0      NS                         \+                                                           NS   NS   \-   \-   Mast/ALND        Ch          10      NED    
              62/F                 L     5.0    T3NxM0      \+                         \+                                                           NS   NS   \-   Ch   Mast/ALND       Ch/HT        32      AWM    
              64/F                 L     1.8    T1NxM0      NS                         \+                                                           NS   NS   \-   \-   BCS/ALND         Ch          10      NED    
              70/F                 L     4.0    T2NxM0      \+                         \+                                                           NS   NS   \-   \-   BCS/ALND        Ch/RT         3      NED    
   Yamasaki (2000) \[[@B25]\]    41/F     R       4.5     T2N0M0      \+                                                       \+                        \-   NS   NS      \-       BCS/Mast/ALND    Ch       16      NED
     Salmo (2001) \[[@B26]\]     46/F     R       4.0     T2N0M0      \+               \+                       NS             NS        NS         NS   \-   \+   NS      \-            BCS        Ch/RT     9       NED
   Zekioglu (2003) \[[@B27]\]    79/F     R       1.5     T1N0M0      \+                                        \+             \+        \-              \+   \+   NS      NS         Mast/ALND      NS       24      NED
              76/F                 L     2.2    T2N0M0      \+                         \+                       \+             \+                   \+   \+   NS   NS      BCS           NS          18      NED    
              65/F                 R     3.5    T2N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS   Mast/ALND        NS          16      NED    
              68/F                 R     7.0    T3N1M0      \+                         \+                       \+             \+                   \-   \-   NS   NS   Mast/ALND        NS          22      NED    
              69/F                 R     1.0    T1N0M0      \+                         \+                       \+             \+                   \+   \+   NS   NS   Mast/ALND        NS          12      NED    
              72/F                 R     1.5    T1N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS      BCS           NS          13      NED    
              60/F                 R     1.0    T1N0M0      \+                         \+                       \+             \+                   \+   \+   NS   NS      BCS           NS          10      NED    
              43/F                 L     0.8    T1N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS      BCS           NS          48      NED    
              60/F                 L     2.5    T2N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS   Mast/ALND        NS          54      NED    
              43/F                 L     5.0    T2N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS      BCS           NS          NS      NED    
              72/F                 L     2.7    T2N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS      BCS           NS          NS      NED    
              72/F                 L     2.7    T2N0M0      \+                         \+                       \-             \+                   \+   \+   NS   NS   Mast/ALND        NS          NS      NED    
    Bergman (2004) \[[@B28]\]    61/F     L       2.5     T2NxM0      \+                                        \+             \-        \-              \-   \-   \-      \-         Mast/ALND      NS       NS      NS
    Bigotti (2004) \[[@B29]\]    56/F     L      18.0     T3N1M0      \+                                        \+             \-        \+              \-   \-   \-      Ch           Mast         Ch       14     D-N0S
    Jochems (2004) \[[@B30]\]    71/F     NS      3.0     T2NxM0      NS                                        \+             \+        \+              \+   \+   \-      \-         Mast/ALND      HT       12      NED
    Sridhar (2004) \[[@B31]\]    58/F     R       2.0     T1NxM0      NS                                                       \-                        \-   \-   NS      \-         BCS/ALND      Ch/RT     18      NED
   Yamamoto (2004) \[[@B32]\]    53/F     NS      6.5     T3N2M0      NS                                        \+                                       NS   NS   NS      NS            NS          NS       34      NED
              75/F                NS     2.0    T2N1M0      NS                         \+                                                           NS   NS   NS   NS      NS            NS          43      NED    
    Berruti (2004) \[[@B33]\]    59/F     NS      NS      T2N0M0      \+                                        \+             \+        \+              \+   \-   NS      \-           Mast         HT       NS      AWM
   Adegbola (2005) \[[@B34]\]    46/F     R       1.0     T1N0M0      NS                                                       \+        \+              \-   \-   \-      \-            BCS        Ch/RT     48      NED
              60/F                 R     1.7    T1NxM0      \+                                                  \+             \+                   \-   \-   \-   \-      BCS          Ch/RT        20     D-NOS   
              61/F                 L     1.7    T1NxM0      NS                                                  \+                                  \-   \-   \-   \-      BCS          Ch/RT         6      AWM    
    Valdes (2006) \[[@B35]\]     41/F    R/MF     1.5     T1NxM0      \+                                                                 \+              \-   \-   NS      \-       Mast/SLNB/Re     Ch       NS      NS
   Fujimoto (2007) \[[@B36]\]    40/F    L/MF     2.0     T1NxM0      \+                                                       \+        \+              \+   \+   \+      \-         Mast/SLNB      HT       36      NED
      Kim (2008) \[[@B37]\]      27/F     L       3.2     T2NxM0      NS                                        \+             \+        \+              NS   NS   NS      \-         BCS/ALND      Ch/RT     18      NED
   Kinoshita (2008) \[[@B9]\]    31/F     L       6.0     T3NxM0      \+                                        \+             \+                        \-   \-   \-      Ch         Mast/ALND      Ch       9      D-NOS
     Stita (2009) \[[@B38]\]     64/F     L       3.0     T2NxM0      \+                                        \+             \+                        \+   \+   NS      \-         Mast/ALND      Ch       8       NED
   Yamaguchi (2009) \[[@B39]\]   51/F     R       3.0     T2NxM0      NS                                                       \+        \+              \-   \-   \-      \-         Mast/ALND      Ch       12      AWM
   Christie (2010) \[[@B40]\]    61/F     L       3.0     T2NxM0      \+                                                       \+        \+              \-   \-   \-      \-         BCS/ALND       Ch       3      D-NOS
     Latif (2010) \[[@B41]\]     53 /F    R       6.0     T3N0M0      NS                                                       \+        \+              \-   \-   \-      Ch         BCS/SLNB       RT       NS      NS
    Honami (2011) \[[@B42]\]     54/F     B     L: 1.0    T1N0M0     L: +                                                      \+        \+              \+   \+   \-      \-            BCS         RT       18      NED
             R: 1.5              R: +                                                                                                                                                                               
   Kawanishi (2011) \[[@B43]\]   67/F     R       0.8     T1NxM0      \+                                                       \+        \+              \+   \+   \-      \-         BCS/ SLNB      HT       12      NED
     Nozoe (2011) \[[@B44]\]     57/F     R       3.0     T2NxM0      NS                                        \+                       \+              \+   \+   \-      \-         Mast/ALND      Ch       NS      NS
     Zhang (2011) \[[@B45]\]     29/F     B     L: 8.5    T1N2M0     L: +                                       \+             \+        \+              \+   \+   \-      \-            BCS         Ch       NS      NS
             R: 2.0              R: +                                                                                                                                                                               
      Su (2012) \[[@B46]\]       75/F     L       4.0     T2N0M0      NS                                                       \+        \+              \+   \+   \-      \-         Mast/ALND      HT       20      NED
     Miura (2012) \[[@B47]\]     72/F    R/MC     1.5     T1N0M0    Both +                                                     \+        \+              \+   \+   \-      NS         Mast/SLNB      NS       NS      NS
   Kawasaki (2012) \[[@B48]\]    41/F     L       0.0     TisN0M0     \+                                                       \+        \+              \+   \+   NS      NS            BCS         NS      101      NED
              45/F                 R     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          80      NED    
              41/F                 L     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          90      NED    
              74/F                 R     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          91      NED    
              28/F                 R     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          77      NED    
              30/F                 L     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          86      NED    
              58/F                 R     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          96      NED    
              36/F                 L     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          64      NED    
              38/F                 R     0.0    TisN0M0     \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          69      NED    
              60/F                 L     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          84      NED    
              42/F                 L     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          73      NED    
              43/F                 R     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          80      NED    
              35/F                 R     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          100     NED    
              70/F                 L     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          93      NED    
              72/F                 R     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          66      NED    
              62/F                 L     0.1    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          88      NED    
              38/F                 R     0.2    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          85      NED    
              73/F                 R     0.3    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          71      NED    
              43/F                 L     0.4    T1N1M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          86      NED    
              42/F                 L     0.5    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          96      NED    
              39/F                 R     0.5    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          74      NED    
              33/F                 R     0.7    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          92      NED    
              36/F                 L     1.5    T1N0M0      \+                                                  \+             \+                   \+   \+   NS   NS      BCS           NS          99      NED    
              68/F                 R     2.5    T2N0M0      \+                                                  \+             \+                   \+   \+   NS   NS     Mast           NS          68      NED    
    \(2012\) \[Present case\]    51/F     R       2.0     T4aN0M0     \+                                                       \+        \+              \+   \-   \-     Ch/RT       Mast/ALND     Ch/HT     13      AWM

^a^Studies included in this table are those available in PubMed as of May 31, 2012. Papers that were excluded from this summary are those in which information was not provided explicitly in the description of the case report or because the results were grouped into cohorts \[[@B12],[@B49],[@B57]\].

^b^Obtained either from clinical history or the final pathology report; for multifocal or multicentric disease the largest tumor was registered.

ALND, axillary lymph node dissection; AWM, alive with metastatic disease; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but cause not otherwise specified; DOD, dead of other disease; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast *in situ* component; LR, local recurrence; M, male; Mast, mastectomy; MC, multicentric; MF, multifocal; NED; no evidence of disease; NS, information not specified; NSE, neuron-specific enolase; NSG, neurosecretory granules; PR, progesterone receptors; R, right; Re, reconstruction; RT, radiation therapy; SLNB, sentinel lymph node biopsy; Syn, synaptophysin.

Patients with primary NECB do not have any distinctive clinical presentation (Table [2](#T2){ref-type="table"}). Indeed on clinical examination the findings are similar to those of any other type of invasive breast cancer. Nodule(s) size ranges from Tis to 18.0 cm and are not generally associated with axillary lymphadenopathy. The majority of tumors are \<2.0 cm and patients are staged with early breast cancer. The radiological features may include a highly-dense mass with a spiculated or microlobulated margin on mamography and/or a homogenously hypoechoic massive lesion with normal sound transmission on ultrasonography \[[@B14]\]. It is also possible for it to be mistaken for benign disease such as fibroadenomas or cysts because the tumor may have clear-cut, circumscribed borders \[[@B14]\]. Distinguishing primary from metastatic NECB is not achieved with breast imaging \[[@B49]\].

###### 

Representative clinical and histopathological features of primary neuroendocrine carcinoma of the breast

                                       **Characteristic**                                                                                                                                       **Features**
  --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                        **Epidemiologic**                                                                                                                                              
                                    Age of diagnosis (years)                                                                                                                                        \>50
                                               Sex                                                                                                                                              Female\>Male
                                    **Physical examination**                                                                                                                                           
                                      Clinical presentation                                                                                                      Single palpable, well-circumscribed nodule (x̅: 2.5cm) or nipple discharge.
                                          Nodal status                                                                                                                                Non-palpable axillary lymph nodes
                                       Carcinoid symptoms                                                                                                                                          Absent
                                       **Histopathology**                                                                                                                                              
                                        Tumor components                                                       Co-existing neuroendocrine and ductal cancer cell populations possibly from divergent differentiation of cancer stem cells (lobular or other types of breast cancer are rare).
                                Multifocality or multicentricity                                                                                                                                    Rare
                                         Growth pattern                                                                                                         Solid carcinoid-like (most common), large cell-type, and small/oat cell-type
                                            Cell type                                                                                                           Homogenous group of plasmacitoid, signet ring, clear cell, or small/oat cells
                                   Histopathological features                                    Nuclear palisading; pseudorosette formation; loss of cell cohesion; intra- and/or extra-cellular mucin content; and abundant eosinophilic cytoplasm and nuclei with stippled ('salt and pepper') chromatin.
                                       Diagnostic markers                                                                                                            Most sensitive and specific: chromogranin A or B and synaptophysin.
   Least specific: neurospecific enolase, CD56, neurofilament triplprotein, and bombin or leu.  
                                       Hormonal receptors                                                                                                                          Estrogen/progesterone receptor positive
                                          HER2 negative                                         
                                       Molecular subgroup                                                                                                                        Luminal A (basal-type has been documented)
                                          **Staging**,                                                                                                                                        TisN0M0: 9 (10.9)
                                   ***n*** (%) (***N***=82)^a^                                                                                                                                T1NxM0: 35 (42.7)
                                        T2NxM0: 27 (32.9)                                       
                                         T3NxM0: 8 (9.8)                                        
                                                                                                                                                                                               T4NxM0: 3 (3.7)

^a^Based on case reports that specified size of the lesion; includes present case.

Before any further action is taken the NECB must be classified as 'primary' or 'metastatic'. Physicians should primarily focus on ruling out breast metastasis from small cell carcinoma of the lung, the gastrointestinal tract, pancreas, and the cervix. Metastatic neuroendocrine carcinoma from other organs cannot be distinguished from primary NECB because histologically they are similar \[[@B50]\]. In this case workup with imaging is fundamental. Differential diagnoses should also include Merkel cell carcinoma, lymphoma, carcinoid tumor, and melanoma \[[@B41]\]. Combining clinical data, radiologic findings, and immunohistochemical stains specific to each tumor provides sufficient evidence to rule out metastatic sources of NECB and other primary tumors \[[@B11]\].

Tumors with neuroendocrine immunoreactivity below the 50% threshold should be considered to have focal neuroendocrine differentiation. Generally these are IDC-not-otherwise specified (IDC-NOS) although lobular or medullary carcinomas can also present this feature. Breast cancers with focal neuroendocrine differentiation typically have 12% to 18% of IHC-positive neuroendocrine cells \[[@B12],[@B13],[@B51]\]. These tumors tend to resemble common histologic types of breast cancer rather than NECB in terms of age of presentation, size, histologic grade, and lymph nodal status \[[@B10]\].

The histogenesis of NECB has not been fully clarified. An initial theory suggested that NECB cancer cells derived from argyrophilic cells of neural crest origin that migrated to the mammary ducts \[[@B2]\]. Another theory supports *in situ* development from neuroendocrine cells naturally found in the breast, but these cells have not been consistently found by other authors \[[@B4],[@B52]\]. A novel hypothesis suggests that NECB results from an early divergent differentiation event in breast carcinogenesis in which neoplastic stem cells differentiate into both epithelial and endocrine lines \[[@B10],[@B53]\]. Molecular analysis studies support this theory because studies have shown that the neuroendocrine component is clonally related to the intraductal component \[[@B54]\] and that the whole tumor itself is of the luminal subtype \[[@B55]\].

Histologically describing the breast *in situ* component is important because this determines which adjuvant treatment regimens are chosen. Simultaneous presence of an intra-ductal component and the absence of other primary sites establish the breast as the primary organ of origin \[[@B11],[@B54]\]. Unlike the histogenesis of other common types of neuroendocrine carcinoma where there is evidence of benign neuroendocrine tumors these precursor lesions are extremely rare in the breast. Of the case reports published so far, only one has described a tumor with co-existing NECB and neuroendocrine cell hyperplasia \[[@B47]\]. Kawasaki *et al.* has also described that neuroendocrine ductal carcinoma *in situ* (DCIS) could be considered a pre-invasive stage of NECB \[[@B56]\]. Neuroendocrine DCIS are frequently underdiagnosed preoperatively because it resembles ductal hyperplasia and intraductal papilloma and sampling is quite difficult \[[@B56]\].

Primary NECB is not associated with any definitive gross pathological characteristics. The breast *in situ* component of primary NECB is usually found as an intraductal lesion co-existing with the neuroendocrine carcinoma component \[[@B49]\].

The breast *in situ* component consistently has histopathological features that include large or dilated ducts with the luminal spaces completely filled; distinctive cells with ovoid, polygonal, and spindle shapes; and a low- or moderate- grade of nuclear atypia \[[@B49],[@B57]\]. Additionally this specific component creates four pitfalls during diagnosis: (1) the invasive component of primary NECB can mimic DCIS \[[@B57]\]; (2) non-specific glandular patterns within the tumor can lead to a diagnosis of IDC-NOS \[[@B51],[@B57]\]; (3) cases of invasive lobular carcinoma or carcinoma with lobular features may not be recognized as having neuroendocrine differentiation \[[@B57]\]; and (4) the intraductal component of primary NECB may be mistaken for atypical intraductal hyperplasia or atypical papilloma \[[@B49],[@B57]\]. In our case we initially overlooked this tumor because the IDC component prevailed on the core biopsy sample and final surgical pathology was necessary to obtain a definitive diagnosis. Over two-thirds of the cases in the literature report initial misdiagnosis later rectified after surgery \[[@B57]\].

Histologically the neuroendocrine component resembles lung and gastrointestinal neuroendocrine tumors. It is characterized by cellular monotony, nuclear palisading, pseudorosette formation, loss of cell cohesion, and abundant eosinophilic cytoplasm and nuclei with stippled ('salt and pepper') chromatin \[[@B49],[@B57]-[@B59]\]. Nevertheless these features *per se* are not sensitive enough to rule in a diagnosis because they are inconsistently present \[[@B57]\]. Pathologists mainly rely on using a panel of the most sensitive and specific IHC neuroendocrine markers (chromogranin A or B and synaptophysin) \[[@B51]\]. Other less specific markers, such as neurospecific enolase \[[@B12]\], CD56 \[[@B15]\], neurofilament triplprotein, and bombin or leu \[[@B12]\], should be avoided. Negative immunoreactivity can be common even in in tumors with a distinctive morphologic growth pattern strongly suggestive of NECB \[[@B51],[@B60]\]. In such cases, further analyses with techniques such as *in situ* hybridization \[[@B61]\] and second opinion are valid options.

Primary NECB comprises a heterogeneous group of histologic subtypes that differ from one another depending on the prevalent growth pattern, cell type, level of invasiveness, and prognosis \[[@B62]\]. Several classifications have been proposed \[[@B3],[@B63]\]. The WHO eventually proposed three histologic categories (solid carcinoid-like, large cell-type, and small/oat cell-type) \[[@B8]\], which they derived from the fact that NECB resembles high-grade small and large cell neuroendocrine pulmonary carcinoma. On another note the concomitant presence of neuroendocrine features and mucin differentiation within the same tumor and even in the same cell (amphicrine cell) is almost exclusive to NECB \[[@B15],[@B51]\]. This characteristic led several authors to establish mucin-producing subtypes \[[@B17],[@B51],[@B64]\]. Although the WHO does recognize the fact that mucinous differentiation occurs in 26% of patients with NECB no changes have been made to their classification. Recently, primary NECB has been classified in terms of molecular taxonomy. Gene expression profiling analysis has shown that this group of tumor is of the luminal type \[[@B55]\]. Basal-type characteristics have only been reported in one patient \[[@B65]\].

Patient outcome is not affected by the size of the neuroendocrine component \[[@B10]\]; instead three histological parameters (histological grade, mucin production, and apocrine differentiation) have more significant impact. The most important histological factor is the histological grade \[[@B66]\], which is to some extent related to the histologic subtype. For example, solid neuroendocrine carcinoma and atypical carcinoids, described as well-differentiated tumors, have a better prognosis \[[@B38]\] than small cell and large cell NECB, which are poorly differentiated and have an unfavorable prognosis \[[@B67]\]. Our case highlights the impact histological grade has on a patient's outcome as we believe this may explain why the patient progressed to metastasis despite receiving optimal treatment. Mucin production is highly relevant because solid papillary carcinomas and mucinous carcinomas produce significantly longer survival times than other subtypes of NECB with no mucin content \[[@B67],[@B68]\]. Similarly the presence of apocrine differentiation has correlated with a better prognosis \[[@B69]\].

Specific recommendations regarding surgical management do not exist. Patients should be treated similarly to IDC whose choice of surgical procedure depends on the tumor's location and clinical stage \[[@B12],[@B49],[@B70]\]. Differentiating 'primary' from 'metastatic' NECB is crucial because the latter does not justify submitting a patient to mastectomy and axillary node dissection \[[@B49]\]. Of the patients reported in the literature 48.3% have undergone mastectomy and 40% axillary lymph node dissection. Confirming negative surgical margins can be difficult, especially from intraoperative frozen sections, because NECB may have pagetoid involvement or a background of neuroendocrine cell hyperplasia can produce artifacts \[[@B47],[@B56]\]. To date there is limited information in the literature regarding safety of oncoplastic breast conservation and immediate breast reconstruction. Thus far only one study has reported the case of a patient that underwent mastectomy followed by deep inferior epigastric perforator flap reconstruction, however the authors failed to describe margin status and disease-free survival \[[@B35]\]. Given the difficulty in assessing tumor margin status for this type of tumor, oncoplastic breast conservation and immediate breast reconstruction may not be beneficial to some patients with primary NECB.

The real challenge with primary NECB lies in choosing the ideal type of cytotoxic therapy. Currently there is no information that indicates what the most efficacious regimen is, but the general consensus is to treat it with chemotherapy regimens for common histologic types of breast cancer \[[@B11],[@B15],[@B62],[@B64]\] and pulmonary small cell carcinoma neuroendocrine carcinoma \[[@B11],[@B41],[@B71]\]. Of the cases that give detailed information on treatment (*n*=39), 28 received neo- and/or adjuvant chemotherapy. Some examples of the chemotherapy regimens reported in the literature include fluorouracil/epirubicin/cyclophosphamide followed by docetaxel; etoposimide and carboplatin or cisplatin; cisplatin/irinotecan; adriamycin and cytoxan or cisplatin; paclitaxel alone; and cyclophosphamide/methotrexate/fluorouracil. Our patient was treated with cisplatin/etoposimide followed by paclitaxel/carboplatinum; the former combination is the most widely used in primary NECB. Radiation therapy appears to be used to a lesser extent than chemotherapy; only 18 patients have received it alone or in combination with chemotherapy.

Because breast biomarkers have only recently become a standard in pathology reports many of the earlier case reports lack this information. As seen in Table [1](#T1){ref-type="table"} primary NECB tends to heterogeneously express ER, PR, and HER-2; this may explain why the overall outcome of these patients varies so much between different cohorts. Of the case reports with complete hormone receptor information available (*n*=18) 9 were triple negative, 7 were ER/PR positive and HER-2 negative, and the remaining 2 had other combinations. In this current case report the patient's tumor was ER positive and PR and HER-2 negative and hormone therapy was accordingly prescribed. The current recommendation is for patients with primary NECB to receive hormone therapy based on their hormonal receptor status \[[@B49]\].

At the time of publication of each case report (*n*=83) 58 patients (69.9%) had no evidence of disease, 8 (9.6%) were alive with local recurrence or metastasis, 5 (6.0%) died of other disease, and 12 (14.5%) died of a cause not specified. Only four cases (4.8%), including ours, of locally-advanced primary NECB have been described, but ours was the only to progress to metastatic disease. In general primary NECB, particularly the small cell carcinoma subtype, is as aggressive as pulmonary neuroendocrine carcinoma \[[@B11],[@B24],[@B29]\]. Both these tumors are characterized by their resistance to multi-modal cytotoxic therapies \[[@B71]\]. Our patient is a clear example of this because although she was treated accordingly limited benefit was observed as she quickly developed widespread metastases.

The few studies that give insight into outcome have mixed results. A study by van Krimpen *et al.* suggested that the prognosis does not differ from that of the more common types of breast cancer \[[@B13]\]. This is in accordance with Miremadi *et al.*'s study that reported that cases of primary NECB have the same mean age, size, histologic grade, nodal status, and prognosis as their non-primary NECB counterparts \[[@B10]\]. It has also been suggested that patients with primary NECB of non-small cell type may even have a better prognosis than patients with IDC or invasive lobular carcinoma \[[@B15],[@B72]\]. Alternatively other studies have described a worse outcome overall \[[@B62],[@B73]\].

Several unsolved issues are frequently discussed in the literature. First of all case series have only analyzed their patients as a homogenous population without taking into consideration the different histologic subtypes \[[@B11],[@B51]\]. Second, standard prognostic parameters, specifically histologic grade, are not consistently taken into account when comparing primary NECB cases with non-NECB \[[@B11],[@B51]\]. In addition to this randomized clinical trials comparing the different treatment regimens and their outcomes have not been carried out. All these unsolved matters are obviously related to the rarity of this tumor. Interestingly enough many of the studies included in this review did not provide essential clinical, histologic, diagnostic, and therapeutic information in their case report, which makes comparing them difficult. In this respect if future cases of primary NECB could be prospectively and collectively registered in a single international database encompassing standard epidemiological information and stratifying patients according to histological and molecular subtype then physicians would have a valuable tool to truly understand this tumor.

Conclusion
==========

Primary NECB has been sporadically reported in the literature since 1963, but formal diagnostic criteria have only been available since 2003. Although primary NECB may have morphological characteristics that resemble classic neuroendocrine tumors the histopathological diagnosis can only be made with neuroendocrine markers. Given that a breast *in situ* component may prevail on a core biopsy samples primary NECB may be easily overlooked preoperatively. Being aware of the existence of this disease may allow for timely diagnosis. Misdiagnosing primary NECB is detrimental because patients may not receive the optimal adjuvant treatment they need. Treating a patient with primary NECB requires simultaneous consideration of both the neuroendocrine and breast *in situ* tumor components. At the moment it is difficult to fully understand this rare tumor because issues such as histogenesis, optimal adjuvant therapy, and prognosis are still unknown. The limited number of patients in the literature have presented in different clinical stages and received different treatment combinations thus the data summarized in this review should be interpreted cautiously.
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